The tobacco addiction treatment field is progressing through innovations in medication development, a focus on precision medicine, and application of new technologies for delivering support in real time and over time. This article reviews the evidence for combined and extended cessation pharmacotherapy and behavioral strategies including provider advice, individual counseling, group programs, the national quitline, websites and social media, and incentives. Healthcare policies are changing to offer cessation treatment to the broad population of smokers. With knowledge of the past and present, this review anticipates what is likely on the horizon in the clinical and public health effort to address tobacco addiction.


Article metrics loading...

Loading full text...

Full text loading...


Literature Cited

  1. 1. US Department of Health and Human Services 2014. The health consequences of smoking—50 years of progress Rep. Surgeon General, US Dep. Health Hum. Serv., Cent. Disease Control Prev., Natl. Cent. Chronic Disease Prev. Health Promot., Off. Smoking Health, Atlanta, GA [Google Scholar]
  2. 2. World Lung Foundation 2015. The Tobacco Atlas Atlanta, GA: Am. Cancer Soc, 5th ed.. [Google Scholar]
  3. Jamal A, Agaku IT, O'Connor E. 3.  et al. 2014. Current cigarette smoking among adults—United States, 2005–2013. Morb. Mortal. Wkly. Rep. 63:1108–12 [Google Scholar]
  4. 4. US Department of Health and Human Services 2012. Preventing tobacco use among youth and young adults Rep. Surgeon General, US Dep. Health Hum. Serv., Cent. Disease Control Prev., Natl. Cent. Chronic Disease Prev. Health Promot., Off. Smoking Health, Atlanta, GA [Google Scholar]
  5. Benowitz NL. 5.  2010. Nicotine addiction. N. Engl. J. Med. 362:2295–303 [Google Scholar]
  6. Benowitz NL. 6.  2009. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu. Rev. Pharmacol. Toxicol. 49:57–71 [Google Scholar]
  7. Hall SM, Prochaska JJ. 7.  2009. Treatment of smokers with co-occurring disorders: emphasis on integration in mental health and addiction treatment settings. Annu. Rev. Clin. Psychol. 5:409–31 [Google Scholar]
  8. Fiore MC, Jaén CR, Baker TB. 8.  et al. 2008. Treating tobacco use and dependence: 2008 update Rep. US Dep. Health Hum. Serv., Public Health Serv., Rockville, MD [Google Scholar]
  9. Cahill K, Stevens S, Perera R, Lancaster T. 9.  2013. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst. Rev. 5:CD009329 [Google Scholar]
  10. Fiore MC, Jaen CR. 10.  2008. A clinical blueprint to accelerate the elimination of tobacco use. JAMA 299:2083–85 [Google Scholar]
  11. Fucito LM, Bars MP, Forray A. 11.  et al. 2014. Addressing the evidence for FDA nicotine replacement therapy label changes: a policy statement of the Association for the Treatment of Tobacco Use and Dependence and the Society for Research on Nicotine and Tobacco. Nicotine Tobacco Res. 16:909–14 [Google Scholar]
  12. Hajek P, West R, Foulds J. 12.  et al. 1999. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch. Intern. Med. 159:2033–38 [Google Scholar]
  13. Stead LF, Perera R, Bullen C. 13.  et al. 2012. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. 11:CD000146 [Google Scholar]
  14. Slemmer JE, Martin BR, Damaj MI. 14.  2000. Bupropion is a nicotinic antagonist. J. Pharmacol. Exp. Ther. 295:321–27 [Google Scholar]
  15. Cryan JF, Bruijnzeel AW, Skjei KL, Markou A. 15.  2003. Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology 168:347–58 [Google Scholar]
  16. Hurt RD, Sachs DP, Glover ED. 16.  et al. 1997. A comparison of sustained-release bupropion and placebo for smoking cessation. N. Engl. J. Med. 337:1195–202 [Google Scholar]
  17. Hays JT, Hurt RD, Rigotti NA. 17.  et al. 2001. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation: a randomized, controlled trial. Ann. Intern. Med. 135:423–33 [Google Scholar]
  18. Gonzales D, Rennard SI, Nides M. 18.  et al. 2006. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist versus sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296:47–55 [Google Scholar]
  19. Evins AE, Cather C, Pratt SA. 19.  et al. 2014. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. JAMA 311:145–54 [Google Scholar]
  20. Tonstad S, Tonnesen P, Hajek P. 20.  et al. 2006. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 296:64–71 [Google Scholar]
  21. Cinciripini PM, Robinson JD, Karam-Hage M. 21.  et al. 2013. Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. JAMA Psychiatry 70:522–33 [Google Scholar]
  22. Williams JM, Anthenelli RM, Morris CD. 22.  et al. 2012. A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. J. Clin. Psychiatry 73:654–60 [Google Scholar]
  23. Anthenelli RM, Morris C, Ramey TS. 23.  et al. 2013. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. Ann. Intern. Med. 159:390–400 [Google Scholar]
  24. Pasternak B, Svanstrom H, Hviid A. 24.  2013. Use of varenicline versus bupropion and risk of psychiatric adverse events. Addiction 108:1336–43 [Google Scholar]
  25. Thomas KH, Martin RM, Davies NM. 25.  2013. Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study. BMJ 347:f5704 [Google Scholar]
  26. Oquendo MA, Galfalvy H, Russo S. 26.  et al. 2004. Prospective study of clinical predictors of suicidal acts after a major depressive episode in patients with major depressive disorder or bipolar disorder. Am. J. Psychiatry 161:1433–41 [Google Scholar]
  27. Singh S, Loke YK, Spangler JG, Furberg CD. 27.  2011. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. Can. Med. Assoc. J. 183:1359–66 [Google Scholar]
  28. Prochaska JJ, Hilton JF. 28.  2012. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 344:e2856 [Google Scholar]
  29. 29. National Comprehensive Cancer Network 2015. Clinical practice guidelines in oncology: smoking cessation Natl. Compr. Cancer Netw., Fort Washington, PA [Google Scholar]
  30. Koegelenberg CF, Noor F, Bateman ED. 30.  et al. 2014. Efficacy of varenicline combined with nicotine replacement therapy versus varenicline alone for smoking cessation: a randomized clinical trial. JAMA 312:155–61 [Google Scholar]
  31. Hajek P, Smith KM, Dhanji AR, McRobbie H. 31.  2013. Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone? A randomised controlled trial. BMC Med. 11:140 [Google Scholar]
  32. Ebbert JO, Hays JT, Hurt RD. 32.  2010. Combination pharmacotherapy for stopping smoking: What advantages does it offer?. Drugs 70:643–50 [Google Scholar]
  33. Ebbert JO, Hatsukami DK, Croghan IT. 33.  et al. 2014. Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial. JAMA 311:155–63 [Google Scholar]
  34. Hong AS, Elrashidi MY, Schroeder DR, Ebbert JO. 34.  2015. Depressive symptoms among patients receiving varenicline and bupropion for smoking cessation. J. Subst. Abuse Treat. 52:78–81 [Google Scholar]
  35. Shiffman S, Ferguson SG. 35.  2008. Nicotine patch therapy prior to quitting smoking: a meta-analysis. Addiction 103:557–63 [Google Scholar]
  36. Bullen C, Howe C, Lin RB. 36.  et al. 2010. Pre-cessation nicotine replacement therapy: pragmatic randomized trial. Addiction 105:1474–83 [Google Scholar]
  37. Carpenter MJ, Jardin BF, Burris JL. 37.  et al. 2013. Clinical strategies to enhance the efficacy of nicotine replacement therapy for smoking cessation: a review of the literature. Drugs 73:407–26 [Google Scholar]
  38. Lindson N, Aveyard P, Hughes JR. 38.  2010. Reduction versus abrupt cessation in smokers who want to quit. Cochrane Database Syst. Rev. 11:CD008033 [Google Scholar]
  39. Ebbert JO, Hughes JR, West RJ. 39.  et al. 2015. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. JAMA 313:687–94 [Google Scholar]
  40. Lerman C, Schnoll RA, Hawk LW Jr. 40.  et al. 2015. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. Lancet Respir. Med. 3:131–38 [Google Scholar]
  41. Gourlay SG, Benowitz NL. 41.  1995. Is clonidine an effective smoking cessation therapy?. Drugs 50:197–207 [Google Scholar]
  42. Hajek P, McRobbie H, Myers K. 42.  2013. Efficacy of cytisine in helping smokers quit: systematic review and meta-analysis. Thorax 68:1037–42 [Google Scholar]
  43. Cahill K, Stead LF, Lancaster T. 43.  2012. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst. Rev. 4:CD006103 [Google Scholar]
  44. 44. World Health Organization 2013. WHO report on the global tobacco epidemic, 2013: enforcing bans on tobacco advertising, promotion and sponsorship World Health Org., Geneva [Google Scholar]
  45. Walker N, Howe C, Glover M. 45.  et al. 2014. Cytisine versus nicotine for smoking cessation. N. Engl. J. Med. 371:2353–62 [Google Scholar]
  46. Stead LF, Buitrago D, Preciado N. 46.  et al. 2013. Physician advice for smoking cessation. Cochrane Database Syst. Rev. 5:CD000165 [Google Scholar]
  47. Prochaska JJ, Benowitz NL, Glantz SA. 47.  et al. 2011. Cardiology Rx for change: improving clinical attention to tobacco use and secondhand smoke exposure in cardiology. Clin. Cardiol. 34:738–43 [Google Scholar]
  48. Prochaska JJ, Fromont SC, Leek D. 48.  et al. 2008. Evaluation of an evidence-based tobacco treatment curriculum for psychiatry residency training programs. Acad. Psychiatry 32:484–92 [Google Scholar]
  49. Carson KV, Verbiest ME, Crone MR. 49.  et al. 2012. Training health professionals in smoking cessation. Cochrane Database Syst. Rev. 5:CD000214 [Google Scholar]
  50. Lancaster T, Stead LF. 50.  2005. Individual behavioural counselling for smoking cessation. Cochrane Database Syst. Rev. 2:CD001292 [Google Scholar]
  51. Stead LF, Lancaster T. 51.  2005. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst. Rev. 2:CD001007 [Google Scholar]
  52. Stead LF, Lancaster T. 52.  2012. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst. Rev. 10:CD008286 [Google Scholar]
  53. Hall SM, Humfleet GL, Munoz RF. 53.  et al. 2009. Extended treatment of older cigarette smokers. Addiction 104:1043–52 [Google Scholar]
  54. Schnoll RA, Goelz PM, Veluz-Wilkins A. 54.  et al. 2015. Long-term nicotine replacement therapy: a randomized clinical trial. JAMA Intern. Med. 175:504–11 [Google Scholar]
  55. Stead LF, Hartmann-Boyce J, Perera R, Lancaster T. 55.  2013. Telephone counselling for smoking cessation. Cochrane Database Syst. Rev. 8:CD002850 [Google Scholar]
  56. Severson HH, Akers L, Andrews JA. 56.  et al. 2000. Evaluating two self-help interventions for smokeless tobacco cessation. Addict. Behav. 25:465–70 [Google Scholar]
  57. Schauer GL, Malarcher AM, Zhang L. 57.  et al. 2013. Prevalence and correlates of quitline awareness and utilization in the United States: an update from the 2009–2010 National Adult Tobacco Survey. Nicotine Tob. Res. 2013:1–10 [Google Scholar]
  58. Civljak M, Stead LF, Hartmann-Boyce J. 58.  et al. 2013. Internet-based interventions for smoking cessation. Cochrane Database Syst. Rev. 7:CD007078 [Google Scholar]
  59. Fraser D, Kobinsky K, Smith SS. 59.  et al. 2014. Five population-based interventions for smoking cessation: a MOST trial. Transl. Behav. Med. 4:382–90 [Google Scholar]
  60. Free C, Knight R, Robertson S. 60.  et al. 2011. Smoking cessation support delivered via mobile phone text messaging (txt2stop): a single-blind, randomised trial. Lancet 378:49–55 [Google Scholar]
  61. Kong G, Ells DM, Camenga DR, Krishnan-Sarin S. 61.  2014. Text messaging-based smoking cessation intervention: a narrative review. Addict. Behav. 39:907–17 [Google Scholar]
  62. Duggan M, Smith A. 62.  2013. Social media update 2013 Pew Res. Cent., Washington, DC. http://www.pewinternet.org/2013/12/30/social-media-update-2013/ [Google Scholar]
  63. Prochaska JJ, Pechmann C, Kim R, Leonhardt JM. 63.  2012. Twitter = quitter? An analysis of Twitter quit smoking social networks. Tob. Control 21:447–49 [Google Scholar]
  64. Stoddard JL, Augustson EM, Moser RP. 64.  2008. Effect of adding a virtual community (bulletin board) to. smokefree.gov: randomized controlled trial J. Med. Internet Res. 10:e53 [Google Scholar]
  65. Danaher BG, Boles SM, Akers L. 65.  et al. 2006. Defining participant exposure measures in Web-based health behavior change programs. J. Med. Internet Res. 8:3e15 [Google Scholar]
  66. An LC, Schillo BA, Saul JE. 66.  et al. 2008. Utilization of smoking cessation informational, interactive, and online community resources as predictors of abstinence: cohort study. J. Med. Internet Res. 10:e55 [Google Scholar]
  67. May S, West R. 67.  2000. Do social support interventions (“buddy systems”) aid smoking cessation? A review. Tob. Control 9:415–22 [Google Scholar]
  68. May S, West R, Hajek P. 68.  et al. 2006. Randomized controlled trial of a social support (‘buddy’) intervention for smoking cessation. Patient Educ. Couns. 64:235–41 [Google Scholar]
  69. West R, Edwards M, Hajek P. 69.  1998. A randomized controlled trial of a “buddy” system to improve success at giving up smoking in general practice. Addiction 93:1007–11 [Google Scholar]
  70. Pechmann C, Pan L, Delucchi K. 70.  et al. 2015. Development of a Twitter-based intervention for smoking cessation that encourages high quality social media interactions through automessages. J. Med. Internet Res. 17:e50 [Google Scholar]
  71. Haines-Saah RJ, Kelly MT, Oliffe JL, Bottorff JL. 71.  2015. Picture me smokefree: a qualitative study using social media and digital photography to engage young adults in tobacco reduction and cessation. J. Med. Internet. Res. 17:e27 [Google Scholar]
  72. Ramo DE, Liu H, Prochaska JJ. 72.  2015. A mixed-methods study of young adults' receptivity to using Facebook for smoking cessation: If you build it, will they come?. Am. J. Health Promot. 29:e126–35 [Google Scholar]
  73. Cobb NK, Jacobs MA, Saul J. 73.  et al. 2014. Diffusion of an evidence-based smoking cessation intervention through Facebook: a randomised controlled trial study protocol. BMJ Open 4:e004089 [Google Scholar]
  74. Chapman S. 74.  2013. Should electronic cigarettes be as freely available as tobacco cigarettes? No.. BMJ346 [Google Scholar]
  75. Etter J-F. 75.  2013. Should electronic cigarettes be as freely available as tobacco? Yes.. BMJ346 [Google Scholar]
  76. Adkison SE, O'Connor RJ, Bansal-Travers M. 76.  et al. 2013. Electronic nicotine delivery systems: international tobacco control four-country survey. Am. J. Prev. Med. 44:207–15 [Google Scholar]
  77. Dockrell M, Morrison R, Bauld L, McNeill A. 77.  2013. E-cigarettes: prevalence and attitudes in Great Britain. Nicotine Tob. Res. 15:1737–44 [Google Scholar]
  78. Goniewicz ML, Lingas EO, Hajek P. 78.  2013. Patterns of electronic cigarette use and user beliefs about their safety and benefits: an internet survey. Drug Alcohol Rev. 32:133–40 [Google Scholar]
  79. King BA, Alam S, Promoff G. 79.  et al. 2013. Awareness and ever-use of electronic cigarettes among U.S. adults, 2010–2011. Nicotine Tob. Res. 15:1623–27 [Google Scholar]
  80. Arrazola RA, Singh T, Corey CG. 80.  et al. 2015. Tobacco use among middle and high school students—United States, 2011–2014. Morb. Mortal. Wkly. Rep. 64:381–85 [Google Scholar]
  81. Wills TA, Knight R, Williams RJ. 81.  et al. 2015. Risk factors for exclusive e-cigarette use and dual e-cigarette use and tobacco use in adolescents. Pediatrics 135:e43–51 [Google Scholar]
  82. Goniewicz ML, Knysak J, Gawron M. 82.  et al. 2014. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob. Control 23:133–39 [Google Scholar]
  83. Caponnetto P, Campagna D, Cibella F. 83.  et al. 2013. EffiCiency and safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLoS ONE 8:e66317 [Google Scholar]
  84. Bullen C, Howe C, Laugesen M. 84.  et al. 2013. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet 382:1629–37 [Google Scholar]
  85. Brose LS, Hitchman SC, Brown J. 85.  et al. 2015. Is the use of electronic cigarettes while smoking associated with smoking cessation attempts, cessation and reduced cigarette consumption? A survey with a 1-year follow-up. Addiction 110:1160–68 [Google Scholar]
  86. Hitchman SC, Brose LS, Brown J. 86.  et al. 2015. Associations between e-cigarette type, frequency of use, and quitting smoking: findings from a longitudinal online panel survey in Great Britain. Nicotine Tob. Res. 171187–94 [Google Scholar]
  87. Cahill K, Perera R. 87.  2011. Competitions and incentives for smoking cessation. Cochrane Database Syst. Rev. 4:CD004307 [Google Scholar]
  88. Volpp KG, Troxel AB, Pauly MV. 88.  et al. 2009. A randomized, controlled trial of financial incentives for smoking cessation. N. Engl. J. Med. 360:699–709 [Google Scholar]
  89. Volpp KG, Asch DA, Galvin R, Loewenstein G. 89.  2011. Redesigning employee health incentives—lessons from behavioral economics. N. Engl. J. Med. 365:388–90 [Google Scholar]
  90. Hilzenrath DS. 90.  2010. Misleading claims about Safeway wellness incentives shape health-care bill. Washington Post Jan. 17, Sec. G01. http://www.washingtonpost.com/wp-dyn/content/article/2010/01/15/AR2010011503319_pf.html [Google Scholar]
  91. 91. US Department of Health and Human Services 2000. Reducing tobacco use Rep. Surgeon General, US Dep. Health Hum. Serv., Cent. Disease Control Prev., Natl. Cent. Chronic Disease Prev. Health Promot., Off. Smoking Health, Atlanta, GA [Google Scholar]
  92. Mills AL, Messer K, Gilpin EA, Pierce JP. 92.  2009. The effect of smoke-free homes on adult smoking behavior: a review. Nicotine Tob. Res. 11:1131–41 [Google Scholar]
  93. Kofman M, Dunton K, Senkewicz MB. 93.  2012. Implementation of tobacco cessation coverage under the Affordable Care Act: understanding how private health insurance policies cover tobacco cessation treatments. Health Policy Inst., Georgetown Univ., Washington, DC. http://www.tobaccofreekids.org/pressoffice/2012/georgetown/coveragereport.pdf [Google Scholar]
  94. Richard P, West K, Ku L. 94.  2012. The return on investment of a Medicaid tobacco cessation program in Massachusetts. PLoS ONE 7:e29665 [Google Scholar]
  95. 95. Healthy People 2020. Leading health indicators. US Dep. Health Hum. Serv. Off. Dis. Prevention and Health Promotion, Washington, DC. http://www.healthypeople.gov/2020/Leading-Health-Indicators [Google Scholar]

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error